RecruitingNot ApplicableNCT05080166

UPLYFT For Lymphoma Survivors

An Intervention for Fear of Cancer Recurrence for Lymphoma Survivors

Sponsor

Dana-Farber Cancer Institute

Enrollment

74 participants

Start Date

Feb 8, 2022

Study Type

INTERVENTIONAL

Conditions

Survivorship Lymphoma

Summary

The main purpose of this study is to field test and pilot an intervention called UPLYFT (Understand and Prevail: Lymphoma Fear of Recurrence Therapy) that includes information about lymphoma survivorship and tools to improve quality of life and reduce lymphoma-related worries among lymphoma survivors.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study (UPLYFT) is developing and testing a mental health support program to reduce fear of cancer recurrence in lymphoma survivors who have recently completed their first round of treatment and are in remission. **You may be eligible if...** - You are 18 or older with a diagnosis of Hodgkin or non-Hodgkin lymphoma - You completed your first line of treatment between 3 and 24 months ago and are in complete remission - You have significant fear of cancer coming back (score of 16 or higher on the validated FCR Inventory-Severity Subscale) - You have access to a computer for video calls **You may NOT be eligible if...** - You have another active cancer - You have untreated or uncontrolled psychotic disorder, bipolar disorder, or borderline personality disorder - You are under 18 Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.